MediciNova to Evaluate MN-221 for the Treatment of Chronic Obstructive Pulmonary Disease Exacerbations
Posted Jul 21 2009 11:32pm
MediciNova, Inc. announced that it plans to evaluate MN-221, a highly selective beta2-adrenergic receptor agonist, for the treatment of chronic obstructive pulmonary disease (COPD) exacerbations. Exacerbations are associated with a significant increase in mortality, hospitalization and healthcare utilization. This would be the second respiratory indication for which MediciNova is currently evaluating the compound.
“We believe there remains an unmet medical need for a safe and effective treatment for COPD exacerbations. Inhaled beta2-adrenergic agonists, which are the current standard of care, are often inadequate to control the symptoms of COPD exacerbations,” said Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer of MediciNova, Inc. “MN-221 may offer a convenient and immediate intravenous delivery for this life-threatening condition for patients who cannot get the full benefit from treatment with inhaled beta2-adrenergic agonists due to severe bronchoconstriction. In addition, we believe that MN-221 may offer the potential for fewer cardiovascular side effects than older beta2-adrenergic agonists due to its greater selectivity for the beta2-adrenergic receptor. ”
Please Follow This Link To Read This Article In It’s Entirety.